AI assistant
Hansa Biopharma — Share Issue/Capital Change 2019
Sep 2, 2019
3057_rns_2019-09-02_301f76a6-6d5d-4738-9311-6a0294421a73.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
PRESS RELEASE
Hansa Biopharma: Issue and re-purchase of class C shares for incentive programme
Lund, Sweden September 2, 2019. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that by virtue of the authorisation by the annual general meeting held on 22 May 2019, the board of directors of Hansa Biopharma AB (publ) has resolved to issue and immediately thereafter re-purchase 715,910 class C shares. The shares are issued and re-purchased in accordance with the incentive programme LTIP 2019, which was adopted by the annual general meeting held on 22 May 2019.
Carnegie Investment Bank AB (publ) will subscribe for the entire issue of new class C shares at a subscription price of SEK 1 per share, corresponding to the quota value of the shares. The entire issue of class C shares will thereafter, in accordance with the board of directors' resolution, be re-purchased by Hansa Biopharma for the same price. The class C shares will be converted into ordinary shares prior to delivery to qualifying participants of LTIP 2019.
The purpose of the re-purchase is to ensure delivery of shares to participants and to secure possible social charges arising as a result of LTIP 2019. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right. Hansa Biopharma has previously issued 705,547 class C shares.
The information was submitted for publication, through the contact person set out below at 17:00 (CET) on September 2, 2019.
Contact information
Klaus Sindahl Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269 E: [email protected]
Rolf Gulliksen Head of Corporate Communications Hansa Biopharma M: +46 (0) 733–328 634 E: [email protected]
About Hansa Biopharma
Hansa Biopharma is harnessing its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.
The Company's lead product, imlifidase, is a unique antibody-degrading enzyme to enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under potential marketing authorization by EMA. Hansa's research and development program is advancing the next generation of the Company's technology to develop novel IgGcleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.
Hansa Biopharma is based in Lund, Sweden and also has operations in the UK and US.
Hansa Biopharma Scheelevägen 22 SE- 223 63 Lund, Sweden Phone: +46 46 16 56 70 www.hansabiopharma.com
Nasdaq OMX Stockholm Ticker: HNSA ISIN: SE 0002148817